SAN ANTONIO, June 7, 2011 /PRNewswire/ -- ImaginAb, Inc. is pleased to announce the availability of custom radiolabeling services for proteins, peptides and other macromolecules as of the 1st of July 2011. This is part of the company's ongoing initiative to broaden the range of product and service offerings to the biopharma and research community and is synergistic with existing activities in custom antibody fragment engineering.
"Over the past 18 months we have grown our core antibody engineering program to over a dozen 'companion diagnostic' programs with pharmaceutical companies in addition to our own internal pipeline" commented Jenny Keppler, President and COO of ImaginAb. "In response to very high demand for our radiochemistry and, in particular our antibody labeling expertise, we have decided to make this capability a standard service offering as part of our recent LA facility expansion."
Protein/peptide labeling services will initially focus on F-18, Cu-64, I-124. Please contact firstname.lastname@example.org for further information and pricing.
Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.
*the technologies described in this press release are available for pre-clinical / non-human use only.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
|SOURCE ImaginAb, Inc.|
Copyright©2010 PR Newswire.
All rights reserved